Search research articles
Contact Us
Filters
Showing results (471-480 of 578) with videos related to
Page
of 58
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 6, 2011
Clinical trials in recurrent ovarian cancer
Michael Friedlander, Edward Trimble, Anna Tinker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2022
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
Antonio González-Martín, Christophe Desauw, Florian Heitz, et al.
The New England Journal of Medicine
|
February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
Journal of Comparative Effectiveness Research
|
December 6, 2024
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, et al.
Oncoimmunology
|
July 28, 2022
Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines
Michal Hensler, Jana Rakova, Lenka Kasikova, et al.
Iscience
|
November 10, 2025
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors
An Coosemans, Jolien Ceusters, Chiara Landolfo, et al.
The Lancet. Oncology
|
November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 13, 2021
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 5, 2021
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, et al.
The New England Journal of Medicine
|
December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.
Page
of 58
Search research articles
Search
Showing results (471-480 of 578) with videos related to
Sort By:
Page
of 58
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 6, 2011
Clinical trials in recurrent ovarian cancer
Michael Friedlander, Edward Trimble, Anna Tinker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2022
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
Antonio González-Martín, Christophe Desauw, Florian Heitz, et al.
The New England Journal of Medicine
|
February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
Journal of Comparative Effectiveness Research
|
December 6, 2024
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, et al.
Oncoimmunology
|
July 28, 2022
Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines
Michal Hensler, Jana Rakova, Lenka Kasikova, et al.
Iscience
|
November 10, 2025
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors
An Coosemans, Jolien Ceusters, Chiara Landolfo, et al.
The Lancet. Oncology
|
November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 13, 2021
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 5, 2021
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, et al.
The New England Journal of Medicine
|
December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.
Page
of 58